L-/N-type calcium channel blockers and proteinuria

Area of Science:

• Nephrology
• Pharmacology
• Cardiology

Background:

• Hypertensive patients with chronic kidney disease (CKD) often require multiple antihypertensive agents.
• Renin-angiotensin system inhibitors (RASi) are first-line due to antiproteinuric and reno-protective effects.
• Achieving target blood pressure and kidney protection with RASi alone is challenging, necessitating second-line therapies.

Purpose of the Study:

• To evaluate the efficacy of L-/N-type calcium channel blockers (CCBs) as second-line antihypertensives in RASi-treated hypertensive patients with CKD and proteinuria.
• To compare the reno-protective effects of L-/N-type CCBs versus L-type CCBs in this patient population.

Main Methods:

• Retrospective analysis of hypertensive patients with CKD and proteinuria treated with RASi.
• Comparison of urinary protein reduction between patients receiving L-/N-type CCBs (cilnidipine) and L-type CCBs (amlodipine) as add-on therapy.
• Assessment of hemodynamic effects on glomerular pressure.

Main Results:

• L-/N-type CCBs, specifically cilnidipine, demonstrated a greater reduction in urinary protein compared to L-type CCBs, such as amlodipine, in RASi-treated patients.
• L-type CCBs can increase glomerular pressure due to afferent arteriole-specific vasodilation, potentially counteracting systemic blood pressure reduction.
• L-/N-type CCBs mitigate glomerular hypertension by dilating both afferent and efferent arterioles, reducing norepinephrine release.

Conclusions:

• L-/N-type CCBs are effective second-line agents for hypertensive patients with CKD and proteinuria already on RASi therapy.
• Their dual blockade of L- and N-type calcium channels offers superior reno-protection by managing glomerular pressure.
• Cilnidipine represents a promising therapeutic option for improving kidney outcomes in this vulnerable patient group.